Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Determine the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SNH-119014 in Adult Subjects With Non-transfusion-dependent Thalassemia

NCT07579949 is registered in ClinicalTrials.gov with ScinnoHub Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07579949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07579949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Determine the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SNH-119014 in Adult Subjects With Non-transfusion-dependent Thalassemia
Lead sponsor
ScinnoHub Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 18, 2026
Completion date
April 29, 2027
Enrollment
30 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

thalassemia